AMEX:TRXC

Stock Analysis Report

Executive Summary

TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.

Risks

  • TransEnterix has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has TransEnterix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.1%

AMEX:TRXC

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

-87.0%

AMEX:TRXC

8.7%

US Medical Equipment

1.7%

US Market

TRXC underperformed the Medical Equipment industry which returned 8.7% over the past year.

TRXC underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

TRXCIndustryMarket
7 Day-0.1%-1.2%1.2%
30 Day-21.1%1.4%4.9%
90 Day-42.0%4.8%3.7%
1 Year-87.0%-87.0%9.6%8.7%3.9%1.7%
3 Year-49.0%-49.0%70.8%65.5%47.2%37.7%
5 Year-82.5%-82.5%130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is TransEnterix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TransEnterix undervalued based on future cash flows and its price relative to the stock market?

1.26x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for TransEnterix to establish if it is available at moderate discount.

Unable to calculate intrinsic value for TransEnterix to establish if it is available at substantial discount.


Price Based on Earnings

TransEnterix is loss making, we can't compare its value to the US Medical Equipment industry average.

TransEnterix is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for TransEnterix, we can't assess if its growth is good value.


Price Based on Value of Assets

TransEnterix is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is TransEnterix expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

3.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

TransEnterix's revenue is expected to grow significantly at over 20% yearly.

TransEnterix is not considered high growth as it is expected to be loss making for the next 1-3 years.

TransEnterix's revenue growth is expected to exceed the United States of America market average.

Unable to compare TransEnterix's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare TransEnterix's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if TransEnterix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has TransEnterix performed over the past 5 years?

-19.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

TransEnterix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare TransEnterix's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare TransEnterix's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if TransEnterix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if TransEnterix has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if TransEnterix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is TransEnterix's financial position?


Financial Position Analysis

TransEnterix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

TransEnterix's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

TransEnterix's level of debt (22.5%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (4.7% vs 22.5% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

TransEnterix has less than a year of cash runway based on current free cash flow.

TransEnterix has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.3% each year.


Next Steps

Dividend

What is TransEnterix's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate TransEnterix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate TransEnterix's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as TransEnterix has not reported any payouts.

Unable to verify if TransEnterix's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as TransEnterix has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of TransEnterix's salary, the management and board of directors tenure and is there insider trading?

4.1yrs

Average management tenure


CEO

Todd Pope (54yo)

6yrs

Tenure

US$3,564,942

Compensation

Mr. Todd M. Pope has been the Chief Executive Officer and President of TransEnterix, Inc. (alternate name SafeStitch Medical, Inc.) since September 3, 2013. He was the president and chief executive officer ...


CEO Compensation Analysis

Todd's remuneration is higher than average for companies of similar size in United States of America.

Todd's compensation has increased whilst company is loss making.


Management Age and Tenure

4.1yrs

Average Tenure

50yo

Average Age

The tenure for the TransEnterix management team is about average.


Board Age and Tenure

6.7yrs

Average Tenure

64yo

Average Age

The tenure for the TransEnterix board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$22,717,54828 Sep 18
Synergy Life Science Partners
EntityCompany
Shares3,614,649
Max PriceUS$6.40

Ownership Breakdown


Management Team

  • Joe Slattery (54yo)

    Executive VP & CFO

    • Tenure: 5.9yrs
    • Compensation: US$2.27m
  • Todd Pope (54yo)

    CEO, President & Director

    • Tenure: 6yrs
    • Compensation: US$3.56m
  • Joshua Weingard (46yo)

    Chief Legal Officer & Secretary

    • Tenure: 6yrs
  • Stephanie Fitts (53yo)

    Vice President of Clinical

    • Tenure: 1.3yrs
  • Mohan Nathan

    Vice President of Global Marketing

    • Tenure: 0yrs
  • Paul Ziegler

    Vice President of Sales

    • Tenure: 4.1yrs
  • Anthony Fernando (47yo)

    Chief Operating Officer

    • Tenure: 2.3yrs
    • Compensation: US$2.26m
  • Eric Smith (47yo)

    Chief Commercial Officer

    • Tenure: 1.1yrs
    • Compensation: US$2.49m

Board Members

  • Bill Starling (66yo)

    Independent Director

    • Tenure: 6.7yrs
    • Compensation: US$190.12k
  • Rick Pfenniger (64yo)

    Independent Director

    • Tenure: 14.7yrs
    • Compensation: US$197.12k
  • Paul LaViolette (61yo)

    Chairman of the Board

    • Tenure: 6yrs
    • Compensation: US$275.76k
  • William Kelley (80yo)

    Independent Director

    • Tenure: 4.7yrs
    • Compensation: US$187.12k
  • Steve Eubanks

    Member of Advisory Board

    • Tenure: 0yrs
  • W. Melvin

    Member of Advisory Board

    • Tenure: 0yrs
  • Todd Pope (54yo)

    CEO, President & Director

    • Tenure: 6yrs
    • Compensation: US$3.56m
  • David Albala

    Member of Advisory Board

    • Tenure: 0yrs
  • Jose Martinez

    Member of Advisory Board

    • Tenure: 0yrs
  • Aurora Pryor

    Member of Advisory Board

    • Tenure: 0yrs

Company Information

TransEnterix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TransEnterix, Inc.
  • Ticker: TRXC
  • Exchange: AMEX
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$194.160m
  • Shares outstanding: 255.64m
  • Website: https://www.transenterix.com

Number of Employees


Location

  • TransEnterix, Inc.
  • 635 Davis Drive
  • Suite 300
  • Morrisville
  • North Carolina
  • 27560
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRXCAMEX (NYSE MKT LLC)YesCommon StockUSUSDSep 2013
2TXDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2013
0LG9LSE (London Stock Exchange)YesCommon StockGBUSDSep 2013

Biography

TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-po ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 00:33
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.